The Peptide NewsroomPeptide research, industry and supply-chain headlines

Weight Watchers Launches GLP-1 Podcast With Dear Media, But the Marketing Funnel Is the Point

By The Peptide Newsroom Desk · Date: 0views 0comments
Topic card: glp-1

Weight Watchers is launching a long-form podcast about GLP-1 drugs, Glossy reports, hosted by former Teen Vogue executive editor Samhita Mukhopadhyay and made with the podcast network Dear Media. The show, called "The Weigh In," launches September 16 and the company says it wants to crush stigma around GLP-1 use.

GLP-1 is the drug class that includes semaglutide (sold as Ozempic and Wegovy) and its competitors, peptide-based medications that mimic a gut hormone involved in appetite and blood sugar regulation. Weight Watchers, 63 years old and rebuilding around those drugs, now sells them through telehealth alongside coaching.

Eight episodes, one big question

The first season runs eight episodes of 45 minutes to an hour, with guests including nutrition expert Dr. Amy Shah, stylist Erin Walsh, The Cut editor-in-chief Lindsay Peoples and SoulCycle founder turned Weight Watchers executive Julie Rice. Mukhopadhyay, who joined the company in March 2025 and has written about her own experience with GLPs for The Cut, told Glossy she plans to take on identity, relationships and culture rather than just how to start.

"There are a lot of assumptions about what it means to take these medications, and there's been a lot of focus on celebrities taking them," she said. Her framing on the drugs themselves is notably unhyped: she hopes to acknowledge that Ozempic and its competitors are not magic bullets, but one piece of a comprehensive medical intervention.

Top of the funnel, and Glossy says so

Glossy is blunt about the commercial logic: the podcast operates as a top-of-funnel marketing endeavor, because Weight Watchers already sells the prescriptions, the telehealth care and the coaching the show will discuss. Mukhopadhyay does not dispute it, telling Glossy that most people do not even know the company sells GLP-1s.

Where the evidence stops

Nothing in this story is a research finding. No trial, outcome figure or published study appears anywhere in it, and the surrounding product line, including AI-powered body composition scans and a wearable-linked "weight health score," is described without any data on what those measures predict.

The open question

A drug seller producing the cultural conversation about its own drug category is not automatically bad journalism, but it is a position with an interest. Whether "The Weigh In" airs the parts of the GLP-1 story that are inconvenient for Weight Watchers is the only test that matters.

Source: Glossy. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

What the Current Semaglutide Research Actually Covers, From Monkey Fat Ratios to Head-to-Head Trials

Semaglutide now functions as the benchmark in obesity research rather than the question, with Lilly reporting head-to-head figures against Ozempic and two companies testing add-ons aimed at preserving lean mass. The muscle-preservation work is still primate data and a half-enrolled Phase 2.

HHS Won't Act Against Six Unapproved Peptides, But FDA Reviewers Advised Against Listing Them

HHS says it will not act against pharmacies compounding BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, despite FDA reviewers recommending against listing all six. The notice sets no end date, adds no test of the finished vial, and is open for public comment through November 13.

Israel's Health Ministry Names Five Peptides in Warning Over Weight-Loss Marketing

Israel's Health Ministry has warned against illegal peptides marketed for weight loss and bodybuilding, naming BPC-157, GHK-Cu, CJC-1295, TB-500 and the investigational obesity drug retatrutide. The ministry says use from unsupervised sources may cause liver and kidney damage, hormonal disorders and blood sugar disruptions.